Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

v3.26.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Mar. 31, 2024   4,792      
Beginning balance at Mar. 31, 2024 $ (121,498) $ 48 $ 708,027 $ (827,380) $ (2,193)
Increase (Decrease) in Stockholders' Equity          
Net loss (115,091)     (115,091)  
Foreign currency translation adjustments, net of income taxes 583       583
Change in fair value of convertible note 0        
Shares issued under employee incentive plans, net (in shares)   157      
Shares issued under employee incentive plans, net   $ 2 (2)    
Warrants exercised related to long-term debt (in shares)   856      
Warrants exercised related to long-term debt 52,984 $ 9 52,975    
Shares issued related to the SEPA, net (in shares)   1,157      
Shares issued related to the SEPA, net 15,828 $ 11 15,817    
Stock-based compensation $ 2,828   2,828    
Ending balance (in shares) at Mar. 31, 2025 6,962 6,962      
Ending balance at Mar. 31, 2025 $ (164,366) $ 70 779,645 (942,471) (1,610)
Increase (Decrease) in Stockholders' Equity          
Net loss (101,046)     (101,046)  
Foreign currency translation adjustments, net of income taxes 594       594
Change in fair value of convertible note (8,444)       (8,444)
Shares issued under employee incentive plans, net (in shares)   121      
Shares issued under employee incentive plans, net 80 $ 1 79    
Shares issued related to the SEPA, net (in shares)   7,555      
Shares issued related to the SEPA, net 75,174 $ 75 75,099    
Stock-based compensation $ (849)   (849)    
Ending balance (in shares) at Mar. 31, 2026 14,638 14,638      
Ending balance at Mar. 31, 2026 $ (198,857) $ 146 $ 853,974 $ (1,043,517) $ (9,460)